Anti-Xa Levels in Critically Ill Patients Receiving Low-molecular-weight Heparin for Thromboprophylaxis in China

S

Southeast University, China

Status

Unknown

Conditions

Critically Ill
Anti-Xa

Treatments

Diagnostic Test: anti Xa level

Study type

Observational

Funder types

Other

Identifiers

NCT03311984
Anti-Xa Level

Details and patient eligibility

About

Critically ill Patients are at high risk to develop deep venous thrombosis. However, despite receiving of a standard dose of Low-molecular-weight Heparin(LMWH), many patients still develop life-threatening embolism. The purpose of this study is to evaluate the anti-Xa levels of different dosing regimens of LMWH in critically ill patients in China.

Enrollment

200 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Adult Critically ill patients

Exclusion criteria

Contraindication to use of LMWH. Intracranial bleeding/stroke, hematoma or bleeding disorder. Use Heparin anticoagulant therapy

Trial design

200 participants in 2 patient groups

LMWH qd
Description:
receiving Low-molecular-weight Heparin(LMWH)qd
Treatment:
Diagnostic Test: anti Xa level
LMWH q12h
Description:
receiving Low-molecular-weight Heparin(LMWH)q12h
Treatment:
Diagnostic Test: anti Xa level

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems